Taxane resistance in prostate cancer is mediated by decreased drug-target engagement is a research paper published in Journal of Clinical Investigation (2020). On theSindex it has a DataRank of 0.598. It has been cited 53 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.598
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NIH, Sanofi
Grant: NIH R01 CA196996,NIH P01 CA163227,SPORE P50 CA090381,NCI R01 CA179100,NCI SPORE in Prostate Cancer 1P50 CA211024,NCI R21 CA216800,DoD PC180637
NCI NIH HHS
Grant: P50 CA090381
NCI NIH HHS
Grant: R01 CA177165
NCI NIH HHS
Grant: P50 CA211024
NCI NIH HHS
Grant: R01 CA196996
NCI NIH HHS
Grant: P01 CA163227
NCI NIH HHS
Grant: R21 CA216800
NCI NIH HHS
Grant: R01 CA179100
National Institutes of Health
Grant: 5R01CA179100-02
Mechanistic Insights Underlying ERG-induced Taxane Resistance in Castration-Resis
National Institutes of Health
Grant: 5R01CA196996-05
Combating Resistance to Antiangiogenic Therapy in Renal Cell Carcinoma
National Institutes of Health
Grant: 1R21CA216800-01A1
Biomarkers of taxane chemotherapy response/resistance in prostate cancer
National Institutes of Health
Grant: 5P50CA090381-05
SPORE in Prostate Cancer
National Institutes of Health
Grant: 1P50CA211024-01A1
Weill Cornell Medicine (WCM) SPORE in Prostate Cancer
National Institutes of Health
Grant: 5P01CA163227-09
Androgen Receptor Action in Castration Resistant Prostate Cancer
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Optimizing combination therapy in prostate cancer: mechanistic insights into the synergistic effects of Paclitaxel and Sulforaphane-induced apoptosis
Additional file 1 of Optimizing combination therapy in prostate cancer: mechanistic insights into the synergistic effects of Paclitaxel and Sulforaphane-induced apoptosis